Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Asset Writedowns and Impairment (2016)

Historic Asset Writedowns and Impairment for Amphastar Pharmaceuticals (AMPH) over the last 4 years, with Q2 2016 value amounting to $114000.0.

  • Amphastar Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $114000.0 in Q2 2016 from the same period last year, while for Dec 2023 it was $114000.0, marking a year-over-year change of. This contributed to the annual value of $2.7 million for FY2023, which is N/A changed from last year.
  • Amphastar Pharmaceuticals' Asset Writedowns and Impairment amounted to $114000.0 in Q2 2016.
  • In the past 5 years, Amphastar Pharmaceuticals' Asset Writedowns and Impairment registered a high of $217000.0 during Q1 2016, and its lowest value of $4000.0 during Q3 2015.
  • In the last 4 years, Amphastar Pharmaceuticals' Asset Writedowns and Impairment had a median value of $120000.0 in 2013 and averaged $113555.6.
  • Over the last 5 years, Amphastar Pharmaceuticals' Asset Writedowns and Impairment had its largest YoY gain of 6410.26% in 2015, and its largest YoY loss of 6923.08% in 2015.
  • Quarter analysis of 4 years shows Amphastar Pharmaceuticals' Asset Writedowns and Impairment stood at $120000.0 in 2013, then crashed by 35.0% to $78000.0 in 2014, then surged by 64.1% to $128000.0 in 2015, then fell by 10.94% to $114000.0 in 2016.
  • Its Asset Writedowns and Impairment was $114000.0 in Q2 2016, compared to $217000.0 in Q1 2016 and $128000.0 in Q4 2015.